ArticleAmerican journal of translational research2025
Denosumab improves bone mineral density, promotes fracture healing, and reduces recurrent fractures in patients with osteoporotic fractures.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of denosumab on bone mineral density (BMD), fracture healing, recurrent-fracture risk, pain, and safety in patients with osteoporotic fractures.
methodsThis retrospective cohort study included 216 patients with osteoporotic fractures treated between January 2019 and June 2023. Patients received either denosumab (60 mg subcutaneously every 6 months; n = 113) or zoledronic acid (5 mg intravenously once annually; n = 103), alongside calcium and calcitriol supplementation. The primary endpoint was the change in lumbar-spine, femoral-neck, and total-hip BMD at 6 and 12 months. Secondary endpoints included serum bone-turnover markers [C-terminal telopeptide of type I collagen (CTX), bone-specific alkaline phosphatase (BALP), procollagen type I N-terminal propeptide (P1NP)], fracture-healing time, 12-month recurrent fracture incidence, pain intensity [Visual Analog Scale (VAS)], function by the Oswestry Disability Index (ODI), analgesic use, and adverse events. Pearson correlation was used to evaluate associations between bone turnover markers and BMD.
resultsAt 12 months, denosumab significantly increased lumbar-spine, femoral-neck, and total-hip BMD compared to zoledronic acid (P < 0.05). CTX and P1NP were significantly lower after 6 and 12 months (P < 0.05) and were inversely correlated with BMD gains (P < 0.05), while BALP showed no correlation. Denosumab significantly shortened fracture-healing time (P < 0.05), improved complete-healing rate (P < 0.05), and reduced recurrence (P < 0.05). VAS, ODI, and analgesic use were all lower in the denosumab group (P < 0.05). The incidence of adverse events was comparable between the two groups (P > 0.05).
conclusionDenosumab substantially enhanced BMD, accelerated fracture healing, reduced recurrent fracture risk, and alleviated pain in patients with osteoporotic fracture, with a safety profile comparable to zoledronic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.